Consensus Biogen Inc.

Stocks

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-10 EDT			5-day change	1st Jan Change
215.43 ^USD	+2.23%		-4.04%	+22.41%

09-09	Biogen Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 09:30 AM
09-08	Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers	RE

Evolution of the Average Target: Biogen Inc.

Evolution of the Target Price: Biogen Inc.

Changes in Analyst Recommendations: Biogen Inc.

8204c.5JKSjT9vKtxbHwHRV5NfEOuDOwcREDGku_0SAv_K9aQ.psLz72giGOkjK3WdAtwrRKfFamA8VFyX1K50NbmYnpe1_MDrWTt9qW5tbg~29a1217ee4f88cb9057f8f7f767d6fd1

Analysts' recommendations: Biogen Inc.

09-03	Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating	MT
08-25	RBC Adjusts Price Target on Biogen to $260 From $240, Maintains Outperform Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240	MT
08-13	Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300	MT
08-10	HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating	MT
08-03	Mizuho Adjusts Price Target on Biogen to $241 From $221	MT
07-30	BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating	MT
07-30	TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating	MT
07-30	Canaccord Genuity Adjusts Price Target on Biogen to $248 From $245, Maintains Buy Rating	MT
07-30	Goldman Sachs Adjusts Price Target on Biogen to $290 From $271, Maintains Buy Rating	MT
07-30	BMO Raises Price Target on Biogen to $208 From $196, Keeps Market Perform Rating	MT
07-30	UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating	MT
07-30	RBC Trims Price Target on Biogen to $240 From $242, Keeps Outperform Rating	MT
07-29	JPMorgan Lifts Biogen Price Target to $210 From $185	MT
07-29	Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating	MT
07-29	Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214	MT
07-28	Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating	MT
07-24	Rothschild & Co Redburn Adjusts Price Target on Biogen to $210 From $190, Maintains Neutral Rating	MT
07-21	BofA Securities Adjusts Biogen Price Target to $215 From $217	MT
07-21	Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating	MT
07-14	Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206	MT
07-13	Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating	MT
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOGEN INC.					+12.56%
	REGENERON PHARMACEUTICALS, INC.					+5.16%
	CSL LIMITED					-0.18%
	MODERNA, INC.					-14.09%
	SAMSUNG BIOLOGICS CO.,LTD.					+35.5%
	UCB					+39.3%
	INCYTE CORPORATION					+1.37%
	INNOVENT BIOLOGICS, INC.					+30.89%
	SWEDISH ORPHAN BIOVITRUM AB					+13.02%
	BRIDGEBIO PHARMA, INC.					+43.4%
	Average					+16.69%
	Weighted average by Cap.					+12.93%